Regeneron Pharmaceuticals Financial Ratios
NASDAQ: REGNHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Regeneron Pharmaceuticals ratio analysis
Regeneron Pharmaceuticals earned a net margin of 31.4% in FY 2025, up from 31.1% a year earlier. Return on equity reached 14.4%, meaning Regeneron Pharmaceuticals generated 0.14 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.06 versus 0.07 the year before, and the current ratio was 4.13.
At the end of FY 2025, REGN traded at 18.7 times earnings; across the 10 fiscal years shown, its year-end P/E ranged from 8.8 to 47.7, with a median of 18.8. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Regeneron Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 18.72 | 18.73 | 25.26 | 18.88 | 8.77 | 15.83 | 20.00 | 18.67 | 36.36 | 47.67 |
| Price / sales | 5.66 | 5.46 | 7.14 | 6.35 | 4.15 | 6.12 | 6.15 | 8.34 | 6.81 | 7.91 |
| Price / book | 2.60 | 2.64 | 3.61 | 3.41 | 3.56 | 4.71 | 3.64 | 4.90 | 6.50 | 8.64 |
| Gross margin | — | — | — | — | — | — | 93.9% | 95.4% | 96.6% | 96.0% |
| Operating margin | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 33.7% | 49.3% | 35.4% | 27.4% |
| Net margin | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 47.5% | 20.4% | 18.4% |
| Free cash flow margin | 28.4% | 25.8% | 29.5% | 36.3% | 40.6% | 23.6% | 30.5% | 35.2% | 17.6% | 20.0% |
| Return on equity (ROE) | 14.4% | 15.0% | 15.2% | 19.1% | 43.0% | 31.9% | 19.1% | 27.9% | 19.5% | 20.1% |
| Return on assets (ROA) | 11.1% | 11.7% | 12.0% | 14.9% | 31.7% | 20.5% | 14.3% | 20.8% | 13.7% | 12.8% |
| Debt / equity | 0.06 | 0.07 | 0.08 | 0.09 | 0.11 | 0.18 | 0.00 | — | — | — |
| Current ratio | 4.13 | 4.73 | 5.69 | 5.06 | 3.56 | 3.63 | 3.67 | 4.47 | 3.82 | 2.56 |
| Revenue growth | 1.0% | 8.3% | 7.8% | -24.3% | 89.1% | 29.6% | 27.4% | -12.4% | 20.8% | 18.4% |
| EPS growth | 8.2% | 10.3% | -9.0% | -46.9% | 135.8% | 65.3% | -13.3% | 105.9% | 34.3% | 39.5% |